169 related articles for article (PubMed ID: 31037122)
1. Anti-tumor effects and potential therapeutic response biomarkers in α-emitting
Ohshima Y; Kono N; Yokota Y; Watanabe S; Sasaki I; Ishioka NS; Sakashita T; Arakawa K
Theranostics; 2019; 9(6):1538-1549. PubMed ID: 31037122
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of radionuclide treatment using α-emitting meta-
Ohshima Y; Sudo H; Watanabe S; Nagatsu K; Tsuji AB; Sakashita T; Ito YM; Yoshinaga K; Higashi T; Ishioka NS
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):999-1010. PubMed ID: 29350258
[TBL] [Abstract][Full Text] [Related]
3. Organic cation transporter 3 mediates the non-norepinephrine transporter driven uptake of meta-[
Ohshima Y; Sasaki I; Watanabe S; Sakashita T; Higashi T; Ishioka NS
Nucl Med Biol; 2022; 112-113():44-51. PubMed ID: 35802985
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M; Shiga T; Takahashi K; Sugawara S; Nomura K; Hanada K; Ishizuka N; Ito H
PLoS One; 2024; 19(5):e0303623. PubMed ID: 38805424
[TBL] [Abstract][Full Text] [Related]
5. Manual on the proper use of meta-[
Ukon N; Higashi T; Hosono M; Kinuya S; Yamada T; Yanagida S; Namba M; Nakamura Y
Ann Nucl Med; 2022 Aug; 36(8):695-709. PubMed ID: 35794455
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent
Sudo H; Tsuji AB; Sugyo A; Nagatsu K; Minegishi K; Ishioka NS; Ito H; Yoshinaga K; Higashi T
Transl Oncol; 2019 Jul; 12(7):879-888. PubMed ID: 31078058
[TBL] [Abstract][Full Text] [Related]
8. Absorbed dose simulation of meta-
Sakashita T; Watanabe S; Hanaoka H; Ohshima Y; Ikoma Y; Ukon N; Sasaki I; Higashi T; Higuchi T; Tsushima Y; Ishioka NS
Ann Nucl Med; 2021 Jan; 35(1):121-131. PubMed ID: 33222123
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
Strickland DK; Vaidyanathan G; Zalutsky MR
Cancer Res; 1994 Oct; 54(20):5414-9. PubMed ID: 7923174
[TBL] [Abstract][Full Text] [Related]
10. NICD inhibits cell proliferation and promotes apoptosis and autophagy in PC12 cells.
Li B; Duan P; Han X; Yan W; Xing Y
Mol Med Rep; 2017 Sep; 16(3):2755-2760. PubMed ID: 28677782
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
[TBL] [Abstract][Full Text] [Related]
12. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
13. Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.
Vaidyanathan G; Strickland DK; Zalutsky MR
Int J Cancer; 1994 Jun; 57(6):908-13. PubMed ID: 8206683
[TBL] [Abstract][Full Text] [Related]
14. Enhanced wild-type p53 expression by small activating RNA dsP53-285 induces cell cycle arrest and apoptosis in pheochromocytoma cell line PC12.
Lin D; Meng L; Xu F; Lian J; Xu Y; Xie X; Wang X; He H; Wang C; Zhu Y
Oncol Rep; 2017 Nov; 38(5):3160-3166. PubMed ID: 29048679
[TBL] [Abstract][Full Text] [Related]
15. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.
Thouënnon E; Pierre A; Tanguy Y; Guillemot J; Manecka DL; Guérin M; Ouafik L; Muresan M; Klein M; Bertherat J; Lefebvre H; Plouin PF; Yon L; Anouar Y
Endocr Relat Cancer; 2010 Sep; 17(3):637-51. PubMed ID: 20483910
[TBL] [Abstract][Full Text] [Related]
16. Identification of Clinical Relevant Molecular Subtypes of Pheochromocytoma.
Saddozai UAK; Wang F; Akbar MU; Zhang L; An Y; Zhu W; Xie L; Li Y; Ji X; Guo X
Front Endocrinol (Lausanne); 2021; 12():605797. PubMed ID: 34234737
[TBL] [Abstract][Full Text] [Related]
17. Human dosimetry of free
Ukon N; Zhao S; Washiyama K; Oriuchi N; Tan C; Shimoyama S; Aoki M; Kubo H; Takahashi K; Ito H
EJNMMI Phys; 2020 Sep; 7(1):58. PubMed ID: 32960387
[TBL] [Abstract][Full Text] [Related]
18. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
19. Transcriptome profiling of neuronal model cell PC12 from rat pheochromocytoma.
Saminathan R; Pachiappan A; Feng L; Rowan EG; Gopalakrishnakone P
Cell Mol Neurobiol; 2009 Jun; 29(4):533-48. PubMed ID: 19194798
[TBL] [Abstract][Full Text] [Related]
20. Leukocyte common-antigen-related tyrosine phosphatase receptor: altered expression of mRNA and protein in the New England Deaconess Hospital rat line exhibiting spontaneous pheochromocytoma.
Yang T; Martignetti JA; Massa SM; Longo FM
Carcinogenesis; 2000 Feb; 21(2):125-31. PubMed ID: 10657947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
